The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
According to a statement from the China’s securities and regulatory commission, it would “guide institutional investors ... to enter the market with greater efforts.” This comes at a time where a clear lack of targeted stimulus from Beijing weighed on market sentiment.
https://www.cnbc.com/2024/02/06/asia-markets.html
What made the dead cat to jump? Trade volume of 7 million HKse. Has there been any significant news?
Twice or even double regular volume days, jumpy times for traders ..
I am beginning to fear the worst for the Amdiz study….an NDA was suggested by end 23 but there has not even been news of the results….
They should tell us the bad as well as the good news….rather than just quietly dropping it into a pipeline update….it was prominent in last year’s milestones and there is no hiding from it.
Having said that, it could just be administrative delays….the Sovlep read out was given in (august/sept?) but missed the Y/E NDA target by a short time.
Indeed, but even the very best trampolines have yet to master perpetual motion.
…it would appear so
The value of the 4 assets licensed to Inmagene is probably not counted towards their future profitability aim….the two assets (IMG 004 and 007) are shown on the Inmagene pipeline as entering Ph 2….the phase 1s ran from 2022-23. Still several years from a regular income stream for HCM
I agree with 1pencil….very difficult to achieve.
It is only CKHH that could do it…and they would need to bid for the whole company…..the NEDs and advisor roles would be critical…..as they would need to consider the fairness and reasonableness of any offer for all shareholders.
HK used to have some rules that allowed creeping takeovers without a formal offer, I am not sure if those rules still exist….but that would require CKHH to buy in the market or perhaps a buy back of shares raising their stake over time…..
CKHH has a number of listed subsidiaries and as far as I am aware has not actively bought any out. Ownership % range from 15% to 75% - It has sold /merged a few of these with other listed companies eg Orange to Mannesmann/Vodafone, HTA (3 in Australia was listed and then merged with Vodafone and then merged again recently (the listing remains), Husky Oil was merged with Cenovus.
It does have large unlisted businesses (and has traded a number of Telecoms entities recently) and I would not be surprised if at some point CKHH looked to merge HCM with another business….whether that is listed or not will depend on the potential partner (eg a PE backed entity would not be, but presumably we would get a cash offer in that case).
CKHH is a relatively benign owner it holds HCM as an investment/Finance asset and while it has supported past development it has not put more cash in for some time and has been content for its ownership share to reduce. I think they will continue with this approach and be happy with a 15%-20% stake in a larger entity in time.
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
Hong Kong, Shanghai & Florham Park, NJ — Friday February 2, 2024: HUTCHMED (China) Limited (“HUTCHMED”)
(Nasdaq/AIM:HCM; HKEX:13) today announced that, Inmagene Biopharmaceuticals (“Inmagene”) has exercised options to license two drug candidates discovered by HUTCHMED, IMG-007 and IMG-004 (the “Options”) pursuant to the terms of the strategic partnership announced on January 11, 2021. Following the exercise of the Options and subject to receipt by HUTCHMED of ordinary shares representing approximately 7.5% of shares (fully diluted) in Inmagene, Inmagene will be granted an exclusive license to further develop, manufacture and commercialize these two drug candidates worldwide.
As part of the partnership, HUTCHMED granted Inmagene exclusive options to multiple drug candidates solely for the treatment of immunological diseases. Since the execution of the Option agreement, Inmagene has funded and led two of these candidates, IMG-004 and IMG-007, to clinical development. For each of the drug candidates, IMG-004 and IMG-007, HUTCHMED is entitled to receive potential payments subject to the achievement of development milestones of up to US$92.5 million and subject to the achievement of commercial milestones of up to US$135 million, as well as royalties upon commercialization.
There are so many hurdles for that to happen it would be very hard to imagine.
The more I look at the markets the more I think those trading are really not interested in company fundamentals.
Pencil, it is just a hypothetical question.
I don’t have much knowledge about such complex topics.
Can you list an example amones ?
(It’s a trivial doubt and I want to stress that it is not specifically about any company.)
Imagine a public listed company where the management has control over majority percentage of the shares, or, held by people and firms linked to the company. Can the management make use of poor market condition and enforce a compulsory buy back of ALL shares held by private and institutional investors and go private? Will it be legally allowed to do so as per stock exchanges’ (for example LSE/ NYSE/HKSE) rules and regulations.
I know it sounds illogical. Thanks if anybody able to clarify.
HK being separate from many China regulatory bodies has some disadvantages….HK could have had Elunate several years ago…..I assume no NRDL rates apply in HK….for the time being.
A few more million in sales can be expected in 2024.
Hope one or two clever strategists working for bigger pharmas are watching today’s news as well as the pipeline.
Market reaction to what I see as positive news.
I think the main issue here now is China, teh entire market and anything Chinese is now considered univestible by most Fund Managers and the entire Chinese market is sinking, fuelled by an impending property sector collapse
Is there a similar online chat forum for HK shareholders to express their concerns and views?On an average, 3 million shares are traded daily at HKSE. What factors might be encouraging buyers over there to buy into this stock?
Has anyone received a reply from the ir department? Luckily, another weekend….
S4 has today announced a share buy back programme, shares currently up 7%
Alibaba co-founders buy more than $200 million worth of shares, sending stock up
https://www.cnbc.com/2024/01/23/alibaba-stock-jack-ma-joe-tsai-buy.html
It could be emails are getting stuck in junk folders, this has happened to me also - try adding Mark Lee, Senior Vice President to subject line, this helped a colleague of mine.
If you still have problems try contacting Tim.Stamper@fticonsulting.com, he can then help pass on messages.
Hutchmed seem to be doing everything right, nothing I can see adverse - hunker down and wait for the storm to pass.
During Mr Hogg’s period, HCM used to get very good coverage in the financial sections of the press, with it’s stock price always in a healthy range. Markets used to treat the company fairly due to its decent pipeline. Now, the picture entirely different. The company has progressed very well with R&D, successfully getting approval for its drug candidates and marketing the same. Also, company has made alliances with other major players in the field resulting in significant royalties. While continuing to do productive progress and having no debts (correct me if I’m wrong) , it has failed to bring cheers to the investors. Share price is less than half its value 2 years ago and has fallen more than 30% since the beginning of the new year. The least, the management could do to help is to release a statement, whether they are ( /are not ) able to see any reason/s for decline in the market valuation.
Absence of a dedicated CEO seems to be the matter.
Hoping to see better days ahead!
A few weeks ago I sold my entire holding and invested it in Nvidia. I have finally given up with the Geo Political risks here. It doesn't seem to matter how successful the Company is or will become, the market and investors are not buying it. I have invested too much time and effort and became emotionally attached to Hucthmed, which is probably not a good thing. Good luck to everyone.
The interesting thing about Christian is that he did look at this bulletin board occasionally and was always keen on picking up investor sentiment. I don't get the impression the current senior leadership team have the same interest in investors.
One concern is about the rapid decline in the sp despite all the good achievements, including marketing a product in US market and also, impending outcome of application for approval for the same drug in Japan and Europe (plus many more). Over the last 3 weeks, sp has fallen by a quarter and the management is yet to say anything.
Regarding getting a reply from the company- 3 years ago, Mr Hogg, (then CEO), had replied to me, in detail, to an email enquiry arising from discussion on this board. He had taken time to respond a private investor’s query. However, I did not receive any response to another email to the investor relations, an year and half age. (Mr Hogg had retired by that time). Pencil , please inform other users of this bb If you get a response from the ir.